Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

in Ann Arbor, Michigan, and the Mayo Clinic in Rochester, Minnesota.

The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x10(10) TCID(50) for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.

Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the

meaning of Section 21E of the Securities Exchange Act of 1934, as

amended. Forward-looking statements, including the Company's expectations

related to the U.S. Phase II sarcoma clinical trial and the Company's

belief as to the potential of REOLYSIN(R) as a cancer therapeutic,

involve known and unknown risks and uncertainties, which could cause the

Company's ac
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... addition of the "Global N-acetylcysteine Industry Report ... The Global N-acetylcysteine Industry Report 2014 is ... state of the global N-acetylcysteine industry. ... industry including definitions, classifications, applications and industry chain ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... with Merck Animal Health to market Neogen,s Igenity ® ... Dairy Heifer Program consists of genomic tests that offer ... of replacement dairy heifers. The genomic tests can be ... an excellent tool in the decision-making process for breeding ...
(Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ) ... process of identifying a successor to Surya N. Mohapatra, Ph.D., ... has formed a search committee, engaged a leading executive recruitment ... Dr. Mohapatra has agreed to continue to serve ...
... 25, 2011 New England Research Institutes (NERI) today ... from the National Institutes of Health (NIH) for the ... (PHN). PHN is a multi-center clinical research network started ... Blood Institute (NHLBI) of the National Institutes of Health, ...
... SEATTLE, Oct. 25, 2011 Cell Therapeutics, Inc. ("CTI" or ... results for the third quarter ended September 30, 2011. ... Company as we move pixantrone one step closer to potential ... Bianco, M.D., CEO of Cell Therapeutics, Inc. "We believe the ...
Cached Biology Technology:Quest Diagnostics Initiates CEO Succession Process 2New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network 2New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network 3Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 5Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 6
(Date:9/18/2014)... from McGill University and the Quebec government have ... Canadian Journal of Fisheries and Aquatic Sciences ... household cleansers, or industrial cleansers, to which they ... small size and buoyancy, they may readily pass ... global contaminant in the world,s oceans, but have ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
(Date:9/18/2014)... and creatively manipulate spoken language is unique to humans. ... million years of human evolution to make this possible ... gene we now have," says Wolfgang Enard, Professor of ... to understand the molecular biological basis of language Enard ... of his latest study, undertaken in collaboration with scientists ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... 2011 Neurotechnology , a provider of ... of MegaMatcher Accelerator 4.0 , the latest ... solution for high-volume, high-speed fingerprint and iris identification. ... enhanced fault tolerance and a new matching algorithm ...
... the Hawai,i Institute of Marine Biology (HIMB) have developed ... part of a hybrid web application titled GeoSymbio ... on symbiotic zooxanthellae called Symbiodinium which are ... other marine organisms like anemones, jellyfish, and corals. ...
... University of Maryland School of Medicine researchers have uncovered ... understanding cardiac arrhythmia and other heart muscle problems. Understanding ... open the door to new treatments. The study, published ... electrical impulses that coordinate contraction in heart and skeletal ...
Cached Biology News:Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 2Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 3Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 4An online global map of coral and zooxanthellae data for climate change study is released 2An online global map of coral and zooxanthellae data for climate change study is released 3UM School of Medicine finds new pathway critical to heart arrhythmia 2UM School of Medicine finds new pathway critical to heart arrhythmia 3
Request Info...
... The integration of 2D polyacrylamide gel electrophoresis ... regarded as a core technology platform for ... power for complex samples limited only in ... small and large proteins. Quantitative image based ...
... Pfx DNA Polymerase is ideal for ... downstream applications such as cloning and ... by a proprietary enzyme preparation containing ... with proofreading (3'Cut Site5' exonuclease) activity. ...
... PLAU N-term Antibody This antibody is ... conjugated synthetic peptide selected within aa 50~150 ... supplied in PBS with 0.09% (W/V) sodium ... protein G column and eluted out with ...
Biology Products: